“Competitor Intelligence “Market overview

Assim Abdel Halim Professional Medical RepresentativeDBU – Merck Saudi Arabia

1. Who We Are . . !

*DORZOLAMIDE 2%+TIMOLOL 5%.*80 SR .*COMBINATION THERAPY.*CARBONIC ANHYDRAZE INHIBITOR + B-BLOKER.*MARKET LEADER.*THE MOST EFFECTIVE & TRUSTED ONE.*UNIQUE DEVICE.

*COSOPT PF : PRESERVATIVE FREE COMBINATION

COSOPT COSOPT PF* TRUSOPT TIMPOTOL

2. Our competitors :

ALLERGAN: ( Lumigan-Ganfort-Alphagan-Combigan ).

ALCON: ( Betoxolol- Travatan-Duotrov-Azopt-Azarga ).

PFIZER: ( Xalatan-Xalacom ).

3. Generic : Jamjoom xola-xolamol .

ALLERGAN BRANDS

ALCON BRANDS*Travantan(66

SR)*Travoprost 0.004%

*Monotharpy

*Duotrov (71.5 SR)*Travan + Timolol

5%*Combination.

*Azopt ( 44 SR ) *Brinzolamide 10%

*Monotherapy

*Azarga ( 64.80 SR)

*Azopt + Timolol 5%

*Combination therapy

*Betoptic (36.8 SR) *Betoxolol 5%*Monotherapy

PFIZER BRANDS

*Xalatan (76 SR )* Latanoprost

0.005%*Monotherapy

*Xalacom ( 89.5 SR )*Xalatan + 5%

Timolol*No Added value

than Xalatan.

Generic product( Jamjoom )

*Xola (34 SR)

*Dorzolami

de

*Xolamol (51 SR )

*Dorzolamid

e + Timolo

l

4. Who will be our main competitors ?

a) Combination dosage forms .b) Generic forms .

• Our key actions :* Clinical credibility – Rapport building – Adapting

our message – Optimum resources allocation.*Anti-generic campaign .

*BRAND vs GENERIC

Figure 1 : INNOVATION.VALUE FOR MONEY.

So, we can lead forever.

T H A N K S